Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 2/20 | 0.55 |
| ▸ | CDK2 | P24941 | 14/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700725 | 0.88 | CAMK2D (0.56) | CAMK2DCDK2HDAC1HDAC3NCOR1 | |
| SCHEMBL699645 | 0.86 | CDK2 (0.67) | CAMK2DCDK2HDAC1HDAC3NCOR1 | |
| SCHEMBL700733 | 0.84 | HDAC1 (0.68) | CDK2HDAC1HDAC3NCOR1HDAC2 | |
| SCHEMBL701179 | 0.81 | CDK2 (0.53) | CAMK2DCDK2HDAC1HDAC3NCOR1 | |
| SCHEMBL699863 | 0.80 | CDK2 (0.57) | CAMK2DCDK2HDAC1HDAC3NCOR1 | |
| SCHEMBL699633 | 0.80 | CAMK2D (0.56) | CAMK2DCDK2HDAC1HDAC3NCOR1 | |
| SCHEMBL699344 | 0.77 | CDK2 (0.48) | CAMK2DCDK2HDAC1HDAC3NCOR1 | |
| SCHEMBL699938 | 0.76 | JAK2 (0.47) | CAMK2DCDK2HDAC1HDAC3NCOR1 | |
| SCHEMBL274821 | 0.76 | CDK2 (0.85) | CDK2KCNH2CDK1 | |
| SCHEMBL699041 | 0.76 | CDK2 (0.68) | CAMK2DCDK2HDAC1IGF1RCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| JP-2011528040-A | — | — | 2011-11-10 | — | — | JP | claimed |
| EP-2303881-A2 | FUSED HETEROCYCLYC INHIBITORS OF HISTONE DEACETYLASE AND/OR CYCLIN-DEPENDENT KINASES | GILEAD SCIENCES, INC. (US) | 2011-04-06 | — | — | EP | claimed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | claimed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CAMK2D 487/4885CDK2 16/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.